Legal battles between pharmaceutical manufacturers and the federal government are creating uncertainty for the 340B program. Companies like Bristol-Myers Squibb, Johnson & Johnson, Eli Lilly, and Sanofi are proposing rebate models to replace upfront discounts, raising concerns about increased costs, administrative complexity, and potential delays in savings. These changes could impact cash flow for covered entities, undermine patient care, and lead to compliance risks. RxTrail offers solutions to streamline operations, ensure compliance, and maximize savings. As legal challenges continue, staying informed and prepared is crucial for maintaining a sustainable, patient-focused 340B program.